On December 19, 2023, Ruike Biotechnology announced that the new adjuvant recombinant herpes zoster vaccine REC610 has received clinical trial approval from the Philippine National Food and Drug Administration.

The preclinical safety evaluation of REC610 was completed by our company, Shandong Xinbo Pharmaceutical Research Co., Ltd. Preclinical studies have shown that REC610 has good immunogenicity and can induce high-level gE antigen-specific CD4+T cell responses and IgG antibodies. Its immune response is not inferior to the control vaccine Shingrix ®。

Herpes zoster is an acute infectious skin disease caused by the reactivation of varicella zoster virus (VZV) lurking in the body. There is no specific drug for shingles, and vaccination is an effective way to prevent shingles. According to research data on herpes zoster vaccines that have been launched globally, compared to attenuated live vaccines, the new adjuvant vaccine can provide stronger cellular immunity and protective efficacy.

At present, the aging of the population is increasing, and the incidence rate of herpes zoster is increasing. It is believed that REC610 will provide a more powerful vaccine option for vaccination.